Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nm-nOMV vaccine displaying SARS-CoV-2 Spike
- Development stage
- Unknown
- Lead developer
- Intravacc
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
Nm-nOMV vaccine displaying SARS-CoV-2 Spike (also known as Avacc 10) is an intranasal subunit vaccine candidate developed by AdJane Biosciences in collaboration with Intravacc. The vaccine utilizes genetically detoxified native outer membrane vesicles (nOMVs) derived from *Neisseria meningitidis* serogroup B as an immunostimulatory platform and adjuvant, which are non-covalently linked to or display a recombinant SARS-CoV-2 Spike protein. Designed primarily as a mucosal booster, the vaccine aims to induce both systemic IgG and local mucosal IgA immune responses at the respiratory tract entry points to prevent infection and reduce viral transmission. It has been evaluated in a Phase I clinical trial where it demonstrated a favorable safety and tolerability profile and successfully induced mucosal immunogenicity.
- Other names
- COVID 2019 vaccine - IntravaccCOVID2019 vaccine - IntravaccCOVID-2019 vaccine - Intravacc
02
Targets
ACE2 (Angiotensin-converting enzyme 2)RBD (SARS-CoV-2 spike receptor-binding domain)SARS-CoV-2 spike
Beyond the preview
Go deeper on Nm-nOMV vaccine displaying SARS-CoV-2 Spike.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nm-nOMV vaccine displaying SARS-CoV-2 Spike.